Skip to content
Screener

Xeris Biopharma Holdings, Inc. XERS Current Debt

Current Debt at other companies

Eli Lilly logo
Eli LillyLLY
$7.05B+23.2%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$11.81M—
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$21.33M+61.4%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$22.5M—
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$5.96M-80.9%
Embecta Corp. logo
Embecta Corp.EMBC
$9.5M0.0%

Other financials

Income statement

See full
Revenue$92.1M+28.7%
Gross profit$79.6M+33.4%
Operating income$5.2M+15.4%
Net income-$31.1M-1,513%
EPS (diluted)-$0.18-1,700%

Balance sheet

See full
Cash & equivalents$121.7M+105%
Total debt$289.4M+12.5%
Total equity-$9.7M+49.6%
Total assets$411.9M+23.1%

Cash flow

See full
Operating cash flow$8.3M+4,440%
CapEx$131.0K—
Free cash flow-$29.1M—

Valuation

See full
Market cap$1.4B+59.2%
Enterprise value$1.57B+45.5%
P/S4.2×+0.6×

Profitability

See full
Gross margin86.6%+4.3pp
Operating margin10.9%+8.4pp
Net margin-5.1%-1.9pp

Returns & leverage

See full
Return on equity-209.8%—
Debt / equity19.9×—
Current ratio1.4×-0.5×

Where this comes from

Reported directly by Xeris Biopharma Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.

The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001867096-26-000065

FAQ

What is Xeris Biopharma Holdings, Inc.'s current debt?
Xeris Biopharma Holdings, Inc. (XERS) reported current debt of $63.78M in Q2 2026.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.

Ask your AI about Xeris Biopharma Holdings, Inc.'s current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude